Our Featured Experts

David F. McDermott, MD
Dr. McDermott on the Role of VEGF Targeted Therapy in RCC
David F. McDermott, MD, director, Biologic Therapy and Cutaneous Oncology Programs, Hematology/Oncology, Beth Israel Deaconess Medical Center, discusses the role of VEGF-targeted therapy in renal cell carcinoma. 
Andrew D. Zelenetz, MD, PhD
Dr. Zelenetz on Nivolumab Plus Ibrutinib in Patients With CLL
Andrew D. Zelenetz, MD, PhD, medical director of Quality Informatics at Memorial Sloan Kettering Cancer Center, discusses an early-phase trial of nivolumab (Opdivo) plus ibrutinib (Imbruvica) in patients with chronic lymphocytic leukemia (CLL).
Oncology Specialists
Publication Bottom Border
Border Publication